Abstract: Aspects of the present disclosure involve a system comprising a computer-readable storage medium storing a program and method to present missed revenue based on competitor data. The program and method provide for receiving indication of a user request to present missed revenue for at least one product made available for purchase by a website; determining a set of competitor products for the at least one product, each competitor product in the set of competitor products having a competitor product price; identifying, based on the determining, a first competitor product within the set of competitor products with a lowest competitor product price; calculating a missed revenue for the at least one product based at least in part on a difference between the product price and the lowest competitor product price for a given time period; and causing display of the missed revenue in association with the at least one product.

Abstract: Aspects of the present disclosure involve a system comprising a computer-readable storage medium storing a program and method for presenting cross-sell products. The program and method provide for receiving indication of a user selection to display cross sell data for at least one product made available for purchase by a website; determining a set of cross-sell products for the at least one product, each cross-sell product in the set of cross-sell products having been previously sold together with the at least one product in association with website; determining, for each cross-sell product in the set of cross-sell products, a set of metrics that relate the cross-sell product to the at least one product; and causing, for each cross-sell product in the set of cross-sell products, display of the respective set of metrics that relate the cross-sell product to the at least one product.

Abstract: Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.

Abstract: Aspects of the present disclosure involve a system comprising a computer-readable storage medium storing a program and method for presenting cross-sell products. The program and method provide for receiving indication of a user selection to display cross sell data for at least one product made available for purchase by a website; determining a set of cross-sell products for the at least one product, each cross-sell product in the set of cross-sell products having been previously sold together with the at least one product in association with website; determining, for each cross-sell product in the set of cross-sell products, a set of metrics that relate the cross-sell product to the at least one product, and causing, for each cross-sell product in the set of cross-sell products, display of the respective set of metrics that relate the cross-sell product to the at least one product.

Abstract: Aspects of the present disclosure involve a system comprising a computer-readable storage medium storing a program and method to present missed revenue based on competitor data. The program and method provide for receiving indication of a user request to present missed revenue for at least one product made available for purchase by a website; determining a set of competitor products for the at least one product, each competitor product in the set of competitor products having a competitor product price; identifying, based on the determining, a first competitor product within the set of competitor products with a lowest competitor product price; calculating a missed revenue for the at least one product based at least in part on a difference between the product price and the lowest competitor product price for a given time period; and causing display of the missed revenue in association with the at least one product.

Abstract: Systems and techniques may be used for product variant analysis. For example, a technique may include receiving pageview counts of specific variants of a product and identifying purchase information corresponding to each of the specific variants of the product. The technique may include aggregating the pageview counts and the purchase information of the specific variants. The technique may include determining an overall conversion rate for the product using the aggregated pageview counts and the aggregated purchase information, and outputting an insight for the product based on the overall conversion rate.

Abstract: Systems and techniques may be used for providing a conversion loss insight. An example technique may include collecting pageviews for a plurality of users at a website, identifying an out of stock item that appeared in a subset of the pageviews during a time period, and retrieving a unit price of the out of stock item and a conversion rate corresponding to the out of stock item during the time period. The technique may include determining a loss indicator corresponding to lost revenue due to the out of stock item based on the subset of the pageviews, the unit price, and the conversion rate. The loss indicator may be output.

Abstract: Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.

Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.

Abstract: The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer.

Abstract: The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer.

Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.

Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.

Abstract: This invention provides beta-carboline compounds of formula I: wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2-mediated diseases such as inflammatory diseases and cancer.

Abstract: This invention provides beta-carboline compounds of formula wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2-mediated diseases such as inflammatory diseases and cancer.

Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

Abstract: The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer.

Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

Abstract: The subject matter of the present invention is directed to novel substituted ?-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I?B kinase is involved.

Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.